WP04 Biobank


 

Work Package Lead: Dr. Jesús Egido

34. INSTITUTO DE INVESTIGACION SANITARIA DE LA FUNDACION JIMENEZ DIAZ – IIS-FJD (ES)

 

Objectives:

  • Prepare the operation manual of blood and urine collection during clinical trial.
  • Maintain the general biobank where all samples will be stored and distributed in a properly manner to researches involved in the proposal.
  • Measure the estimated glomerular filtration rate (GFR) as well as the gold standard markers of glomerular damage as component of the primary outcome (microalbuminuria and albumin/creatinine ratio).
  • Determine a number of well –established biomarkers on inflammation, endothelial dysfunction and oxidative stress.
  • Examine plasma biomarkers involved in vascular damage.
  • Measure plasma biomarkers of diabetic retinopathy development.
  • Test the hypothesis that metabolomic profiling helps to identify patients at risk of developing microvascular complications.
  • Correlate the different biomarkers with other clinical and imaging data.
  • Search for a panel of biomarkers that could herald the appearance of micro and macro vascular involvement
  • Study the influence of different therapeutic approaches on the biomarkers blood levels.

 

Main tasks:

  • Storage of blood samples and transfer them as well as data information to partners.
  • Estimation of the renal function (eGFR) and the early glomerular damage (albumin creatinine ratio), at baseline and final study visits.
  • Quantification of diagnostic value of known plasma biomarkers of inflammation, oxidative stress, endothelial dysfunction and vascular damage (FJD (partner 4) and CNR (partner 12).
  • Quantification of diagnostic value of plasma biomarkers of diabetic retinopathy development (Dr Rafael Simó Partner 17).
  • Establishment of the metabolic fingerprint of high risk for microvascular complications and its contribution to correct classification over other risk factors and biomarkers. (Dr. arcia-Dorado from Partner 1 (FIRCAVA).
  • Correlation of different biomarkers, individually or as a panel, with the clinical and imaging data to assess global prognostic information.

 

Scroll to Top